Table 1. Patient characteristics.
BMI – body mass index. IQR – interquartile range. PPI – proton pump inhibitor. SD – standard deviation. SSc – systemic sclerosis.
| SSc | Control | p-value | |
|---|---|---|---|
|
| |||
| n | 38 | 38 | |
|
| |||
| Age, years, mean+/-SD | 52 +/- 9 | 53 +/- 13 | 0.903 |
|
| |||
| Gender (F/M) | 35/3 | 21/17 | <0.001 |
|
| |||
| Ethnicity, n (%) | 0.430 | ||
| Not Hispanic or Latino | 26 (68) | 29 (76) | |
| Asian | 0 (0) | 1 (3) | |
| Hispanic or Latino | 7 (18) | 3 (8) | |
| Unknown | 5 (13) | 5 (13) | |
|
| |||
| BMI, median (IQR) | 24 (20 – 29) | 27 (23 – 30) | 0.097 |
|
| |||
| PPI/dose, n (%) | |||
| Rabeprazole 20mg BID | 2 (5) | 2 (5) | |
| Dexlansoprazole 60mg BID | 6 (16) | 5 (13) | |
| Esomeprazole 40mg BID | 9 (24)1 | 10 (26) | |
| Esomeprazole 20mg BID | 1 (3) | 1(3)3 | |
| Omeprazole 40mg BID | 6 (16) | 6 (16) | |
| Omeprazole 20mg BID | 5 (13) | 5 (13) | |
| Lansoprazole 30mg BID | 1 (3) | 1 (3) | |
| Pantoprazole 40mg BID | 7 (18)2 | 7 (18) | |
| Pantoprazole 20mg BID | 1 (3) | 1 (3)4 | |
|
| |||
| Hiatal hernia, n (%) | 0.967 | ||
| None | 21 (55) | 22 (58) | |
| 1-2 cm | 12 (32) | 11 (29) | |
| 3-4 cm | 5 (13) | 5 (13) | |
|
| |||
| Indication for reflux monitoring, n (%) | 0.226 | ||
| Typical reflux symptoms | 23 (61) | 15 (40) | |
| Extraesophageal symptoms | 11 (29) | 19 (50) | |
| Other symptoms | 2 (5) | 3 (8) | |
| Pre-lung transplant evaluation | 2 (5) | 1 (3) | |
1
One SSc patient was on esomeprazole 60mg BID.
2
One SSc patient was on pantoprazole 40mg TID.
3
Matched control was on esomeprazole 40mg DAILY.
4
Matched control was on pantoprazole 40mg daily.